Man Group
VERV

Man Group’s Verve Therapeutics VERV Stock Holding History

Man Group’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-38,687
Closed -$177K – 2402
2025
Q1 		$177K Buy
+38,687
New +$259K ﹤0.01% 2047
2024
Q4 		– Sell
-55,722
Closed -$270K – 2214
2024
Q3 		$270K Sell
55,722
-69,869
-56% -$406K ﹤0.01% 1789
2024
Q2 		$613K Buy
125,591
+110,456
+730% +$694K ﹤0.01% 1632
2024
Q1 		$201K Buy
15,135
+3,717
+33% +$49.3K ﹤0.01% 2010
2023
Q4 		$159K Buy
+11,418
New +$142K ﹤0.01% 1942

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Man Group's VERV Position: Q2 2025 in Review

Man Group sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 38,687 shares — an estimated $177K sold.

Man Group first reported a position in VERV in Q4 2023 and held it in 5 quarters. The position peaked at $613K in Q2 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Man Group reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Man Group sold 38,687 Verve Therapeutics shares in Q2 2025, an estimated $177K.
  • Man Group first reported a position in Verve Therapeutics in Q4 2023 and held it in 5 quarters.
  • Man Group's Verve Therapeutics position peaked at $613K in Q2 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Man Group's 13F filing for Q2 2025, filed 14 Aug 2025.